<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Splenic marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e>), the most common primary <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of spleen, is poorly understood at the genetic level </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, using whole-genome DNA sequencing (WGS) and confirmation by Sanger sequencing, we observed mutations identified in several genes not previously known to be recurrently altered in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>In particular, we identified recurrent somatic gain-of-function mutations in NOTCH2, a gene encoding a protein required for marginal zone B cell development, in 25 of 99 (∼25%) cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e> and in 1 of 19 (∼5%) cases of nonsplenic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZLs</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>These mutations clustered near the C-terminal proline/<z:chebi fb="6" ids="14321,29987">glutamate</z:chebi>/serine/threonine (PEST)-rich domain, resulting in protein truncation or, rarely, were nonsynonymous substitutions affecting the extracellular heterodimerization domain (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>NOTCH2 mutations were not present in other B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and <z:hpo ids='HP_0001909'>leukemias</z:hpo>, such as <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e>; n = 15), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>; n = 15), low-grade follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL; n = 44), hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (HCL; n = 15), and reactive <z:mp ids='MP_0000688'>lymphoid hyperplasia</z:mp> (n = 14) </plain></SENT>
<SENT sid="5" pm="."><plain>NOTCH2 mutations were associated with adverse clinical outcomes (relapse, histological transformation, and/or <z:hpo ids='HP_0011420'>death</z:hpo>) among <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e> patients (P = 0.002) </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that NOTCH2 mutations play a role in the pathogenesis and progression of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SMZL</z:e> and are associated with a poor prognosis </plain></SENT>
</text></document>